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Pycnogenol® (a registered trademark of Horphag Research Ltd.) is French maritime pine bark extract of the outer bark of Pinus 
pinaster Ait. Subsp. atlantica. Its specifications are described in the USP 28 - Dietary supplements. Pycnogenol has strong antioxi-
dant profile proven by in vitro and in vivo studies and further confirmed in clinical trials. Its strong antioxidant profile, vasodilator
activity, antithrombotic effect and collagen stabilizing property make it a unique health product. In humans, Pycnogenol has been 
shown to lower blood pressure in mild to moderate hypertensive individuals and blood glucose levels in diabetics. In this review the 
diverse biological effects of Pycnogenol are presented and discussed using a target-oriented approach, in health and disease condi-
tions like edema, inflammation, chronic venous insufficiency, deep vein thrombosis, diabetes, diabetic retinopathy, and hypertension.
The future trends are the continuous efforts proving its efficacy in conditions which involves oxidative stress and inflammation.
Recent preliminary study utilizing “high throughput” methodology and nutrigenomics approach are able to provide a new insight 
into the molecular mechanism of the biological activity of this botanical sourced nutraceutical. Biomed Rev 2005; 16: 49-57. 
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INTRODUCTION
Pycnogenol® (a registered trademark of Horphag Research 
Ltd.) is French maritime pine bark extract of the outer bark 
of Pinus pinaster Ait. Subsp. atlantica. Its specifications
are described in the USP 28 - Dietary supplements (1). It is 
generally recognized as safe (GRAS) in the USA. Pycnogenol 
has strong antioxidant profile proven by experimental in vitro 
and in vivo studies and further confirmed in clinical trials (2).
The historical development of Pycnogenol and the utilization 
of the pine bark as a health promoting botanical have been 
reviewed (3). The concept of orally administered Pycnogenol, 
either as “stand alone product” or in combination with other 
food ingredients, was developed during last two decades. 
Numerous clinical trials have investigated the efficacy of oral
Pycnogenol in individuals with chronic venous insufficiency
and diabetic retinopathy (4-9). Most of the clinical data on 
Pycnogenol are highlighted in different monographs and 
reviews (10-12). 
The objective of present paper is to review the multifaceted 
biological profile of Pycnogenol using a target-oriented
approach, with a special focus on cardiovascular health and 
glucose control.
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BIOLOGICAL PROFILE OF PYCNOGENOL
Antioxidant and anti-inflammatory activities
The antioxidant and anti-inflammatory effects of Pycnogenol 
are demonstrated by in vitro and in vivo models and confirmed
in clinical studies. These include: (i) antioxidant and free 
radical scavenging activity (13-22), (ii) sparing activity of 
α-tocopherol and recycling of ascorbate radical (23), (iii) 
inhibition of lipid peroxidation (24), (iv) protection of nerve 
cells against β-amyloid, or glutamate induced toxicity (25), 
(v) protection of erythrocytes in G6PD deficient human (26),
(vi) stimulation of antioxidant defense system (27-29), (vii) 
improving endogenous antioxidant mechanisms in antioxidant 
deficient, diabetic rats (30-32), (viii) increased antioxidant 
capacity/activity in human (33-34), (ix) antierythema, 
antioedema, and anti-inflammatory effects (17,35-38), (x) 
inhibition of proinflammatory cytokine actions (39), (xi) 
inhibition of matrix metalloproteases activity (40), (xii) 
inhibition of histamine release from mast cells (41) (xiii) 
wound healing effects (42), and (xiv) clinical studies in 
different health and disease conditions (43-55).
Antioxidant profile: in vitro studies
Several studies have reported that Pycnogenol is a powerful 
free radical scavenger and/or antioxidant in vitro. Oxygen 
free radical (hydroxyl and superoxide) scavenging activity 
of Pycnogenol has been assessed by using a highly sensitive 
electron spin resonance spectrometer and compared to other 
bioactive free radical scavengers like Ginkgo biloba and green 
tea extract. Analogues of vitamin C and vitamin E were used 
as reference standards for hydroxyl radical scavenging activity 
and superoxide dismutase (SOD) was used as the reference 
standard for superoxide anion scavenging activity (19). In 
another study, murine macrophages have been activated by 
the bacterial wall component lipopolysaccharide (LPS) and 
interferon- γ (IFN-γ) in order to induce the expression of 
large amounts of the enzyme nitric oxide synthase (NOS). 
Pycnogenol was found to be a potent free radical scavenger 
of hydroxyl, superoxide and nitric oxide (NO) radicals (13-
14). It increases life span of ascorbate radical and helps in 
regeneration of vitamin E (23). In addition, it was found to be 
resistant to the action of heat and ascorbate oxidase (19). 
 In two different in vitro studies, bovine vascular endothelial 
cells were treated with Pycnogenol before subjecting them to 
oxidative stress induced by t-butyl hydroperoxide (t-BHP). 
LDH release and malondialdehyde (MDA) respectively 
were utilized as biological markers to assess cell death and 
lipid peroxidation. Preincubation of endothelial cells with 
Pycnogenol at concentrations 10-80 µg/ml for 16 hours 
increased the cell viability after t-BHP treatment and, in 
addition, caused a dose-dependent decline in MDA induced 
by t-BHP (18,24). 
In another independent in vitro study model, bovine retina 
was used as the tissue substrate to assess the capacity of 
Pycnogenol in protecting lipids from peroxidation expressed as 
formation of thiobarbituric acid reactive substances (TBARS). 
Pycnogenol significantly inhibited lipid peroxidation in a dose
dependent manner at a concentration as low as 25 ng/ml and 
no damage to lipids were detected at a concentration of 250 
ng/ml. In the same study Pycnogenol was found relatively 
more effective than a standardized extract from grape seeds, 
ascorbate, α-tocopherol, and lipoic acid (21). The antioxidant 
activity of Pycnogenol was further confirmed in an independent
laboratory using three different in vitro models addressing the 
oxidative burst, LDL oxidation and iron/ascorbic acid system 
as oxidant challenges on different substrates. Pycnogenol 
exhibited a concentration-dependent inhibition of oxidative 
burst triggered by zymosan in J774 murine macrophages in 
vitro. Pycnogenol when co-incubated with copper sulphate 
used to oxidize human plasma LDL (formation of TBARS 
used as markers) resulted in inhibition of LDL oxidation in 
a concentration dependent manner. Pycnogenol significantly
minimized the strand cleavage (measured by agarose gel 
electrophoresis) in pBR322 plasmid DNA caused by hydroxyl 
radicals generated by iron/ascorbic acid (20). 
 Pretreatment with LPS of murine macrophages (RAW 264.7) 
leads to increased expression and release of proinflammatory
cytokines, such as interleukin-1 β (IL-1β). Incubation with 
Pycnogenol was associated with a dose-dependent decrease 
in the production of proinflammatory mediators. According
to this report, Pycnogenol has been found to be able to block 
the activation of two major transcription factors, NF-κB and 
AP-1, involved in the production of IL-1β (39). Further, the 
treatment with Pycnogenol induced a concentration-dependent 
increase in intracellular glutathione (GSH), GSH peroxidase 
(GSH-Px) and GSH disulphide reductase (GSSG-R), SOD 
and catalase (CAT) levels expressed as per mg of protein and 
therefore the enhancement of cellular endogenous antioxidant 
activity (27-29).
 
Antioxidant and anti-inflammatory profile:  
in vivo animal studies
Pycnogenol was shown to have remarkable free radical 
scavenging activity in vitro and anti-inflammatory activity
in vivo (17). Anti-inflammatory and wound healing effects
were demonstrated subsequently (35-36,42). There is a 
body of experimental evidence indicating that oxidative 
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stress is involved in the pathophysiology of diabetes and its 
complications. In streptozotocin-induced diabetic rats the GSH 
to GSSG ratio and the activities of endogenous antioxidant 
enzymes (SOD, CAT, GSH-Px, GSSG-R) were significantly
increased after Pycnogenol administration. The activity of γ-
glutamyl transpeptidase (γ-GT), and enzyme in the pathway 
of GSH synthesis, was also increased. These changes were 
associated with a significant decrease in blood glucose levels
in diabetic rats (30). Another study from the same laboratory 
further showed that Pycnogenol administered alone or in 
combination with β-carotene, once again increased GSSG-R 
activity (31). 
The experiments were repeated focusing on diabetic 
retinopathy. Decreased retinal γ-GT activity of diabetic rats 
was normalized by the administration of Pycnogenol alone or 
in combination with β-carotene. On the other hand, elevated 
activity of SOD in diabetic retina, which is considered an 
indication of a response to a “constitutive” oxidative stress 
was normalized by Pycnogenol and β-carotene combination 
(32). The results obtained from the above three studies indicate 
that Pycnogenol significantly affects intracellular antioxidant
defence mechanisms in streptozotocin-induced diabetic rats.
Antioxidant profile: clinical research
Clinical research data on Pycnogenol are provided based 
on its antioxidant activity in healthy volunteers. The effect 
of Pycnogenol on plasma antioxidant defenses in human 
was demonstrated by a significant increase of oxygen
radical absorbance capacity (ORAC) in plasma throughout 
the Pycnogenol supplementation period of three weeks. In 
addition to its ability to enhance plasma antioxidant capacity, 
Pycnogenol significantly reduced LDL-cholesterol levels and
increased HDL-cholesterol levels in the blood (33). In another 
independent double-blind study, Pycnogenol significantly
improved erectile dysfunction, from moderate to mild stage. 
The same study reports a simultaneous significant increase of
plasma antioxidant activity was observed. The level of total 
cholesterol decreased from 5.41 to 4.98 mmol/L associated 
with a decrease LDL cholesterol from 3.33 to 2.78 mmol/L 
(34). 
An acute exposure to ultraviolet rays (UVR) leads to 
inflammatory response and skin erythema. The exposure
to UVR is to be considered one of the major pro-oxidant 
challenges, and stimulates, as a tissue response, the expression 
of many proinflammatory genes such as for tumor necrosis
factor-alpha (TNF-α), IL-1α, IL-1β, IL-6, and IL-8. All these 
cytokines contain NF-κB binding sites in the 5’flanking region
of their encoding gene. 
The preventive effects of orally supplemented Pycnogenol 
against UV-induced skin erythema was studied. In addition, 
the inhibitory effects Pycnogenol on NF-κB -dependent gene 
expression, chosen as a marker of proinflammatory response
induced in spontaneously transformed human keratinocyte cell 
line (HaCaT) after UV exposure (37). In this study, Pycnogenol 
produced a significant increase in the dose of UVR necessary to
achieve standardized erythema response (minimum erythema 
dose, MED) in the skin of human subjects. The activation of 
the proinflammatory and redox-regulated transcription factor
(NF-κB) plays a major role in the UVR-induced erythema. 
Pycnogenol inhibited UVR-induced NF-κB-dependent 
gene expression in a concentration-dependent manner. This 
inhibitory mechanism possibly contributes to an antierythema 
effect (37). 
Oxidative stress is also involved in pathogenesis of other 
clinical conditions like skin ageing, erythema, melasma, 
abnormal sperm morphology, and gingival bleeding and 
plaque formation. The effects of Pycnogenol were studied 
independently in these conditions. Supplementation with 
Pycnogenol along with other micronutrients in a formulation 
Evelle improved visible signs of skin aging, increased skin 
elasticity and decreased skin roughness (53). Pycnogenol 
supplementation provided relief from erythema and 
melasma (37,43). The average melasma area and intensity 
of pigmentation were found to be significantly reduced after
supplementation (43). Pycnogenol, possibly by its antioxidant 
capacity, has also been found to improve abnormal sperm 
morphology and its functions (44). Supplementation therapy 
provided relief from pain in dysmenorrhea in an open clinical 
study (51). 
Other beneficial effects of Pycnogenol due at least in part
to its anti-inflammatory potential have been demonstrated
in asthma (54-55) targeting leukotrienes (55) and histamine 
release (41). Similarly, the incorporation of Pycnogenol in 
chewing gum was associated with decreased gingival bleeding 
and plaque formation. Also this effect has been attributed to 
its antioxidant and anti-inflammatory activities (45).
Vasodilatory effects and antiplatelet activity 
Pycnogenol stimulates the activity of endothelial NOS (e-
NOS) in vitro and in vivo in isolated rat aortic rings (56) as 
well as human sperms (46). The constitutive form of e-NOS 
catalyses the synthesis of NO generating a relaxing signal 
through cyclic GMP to smooth muscles cells underlying 
endothelial cells. Furthermore, NO reacts with blood platelets 
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and prevents their aggregation.
Adrenaline, as well as noradrenaline, generally recognized 
as stress hormones, are very potent vasoconstrictors. In 
experiments with isolated aortic rings from rats, Pycnogenol 
inhibited the vasoconstriction induced by these stress hormones. 
The effect was dose dependent and could not be observed after 
removal of endothelium suggesting that the observed effect 
was mediated by the induction of NO generation by endothelial 
cells (56). Smokers usually present higher levels of stress 
hormones than non-smokers and therefore have high platelet 
reactivity. Pycnogenol administration to smokers at a dose of 
100 mg significantly decreased platelet reactivity. This effect
was similar to that induced by the classical cycloxigenase-2 
inhibitor aspirin (at a dose of 500 mg) without the typical 
increase in bleeding time normally observed after aspirin 
administration (47). The antiplatelet effect of Pycnogenol was 
dose-dependent within a dose range between 25 and 200 mg 
(48). Microvascular blood flow in human nail capillaries has
been shown to be improved after administration of Pycnogenol 
in an independent clinical study (50). In a double blind, 
placebo-controlled crossover study performed in 11 patients, 
supplementation with Pycnogenol in a daily dose of 200 mg, 
normalized the blood pressure with mild hypertension and 
lowered plasma thromboxane levels (49). 
In another double-blind, placebo-controlled trial 
performed in 58 subjects, supplementation of 100 mg of 
Pycnogenol per day significantly decreased the consumption
of the antihypertensive medicine, the calcium channel blocker 
nifedipine normally required to control hypertension. Plasma 
levels of the vasoconstrictor endothelin-1 were reduced in 
association with a significant increase in plasma concentration
of the vasodilator prostacyclin (52). 
Collagen stabilizing properties
Reactive oxygen species (ROS) activate matrix metallopro-
teinases (57) and thus play a significant role as signaling
molecules to contribute to cell injury and collagen proteolysis. 
A dysfunction in the regulation of the activity of these enzymes 
contributes to pathogenesis of various chronic inflammatory
diseases. Pycnogenol and its metabolites have been shown to 
produce dose-dependent inhibitory effects on these enzymes and 
thus contribute to collagen stabilizing properties (58). Moreover, 
a specific affinity of Pycnogenol for collagen and elastin has 
been shown to be able to shield and protect these proteins 
from proteolytic degradation. This effect on structural proteins 
therefore contributes to the “sealing effect” of Pycnogenol 
increasing the integrity of small blood vessels (59).
ROLE OF PYCNOGENOL IN CARDIOVASCULAR DISEASE AND 
GLUCOSE CONTROL
Chronic venous insufficiency and  deep vein
thrombosis
Pycnogenol has been shown to produce beneficial effects in
chronic venous insufficiency. The symptoms improvement 
score showed a statistically significant reduction in the feeling
of heavy legs, swelling and pain in patients treated with 
Pycnogenol as observed in three independent double blind 
clinical studies performed in patients with chronic venous 
insufficiency (CVI). The oedema was the more responsive
sign to treatment in these studies (5-7). 
Two independent studies have been reported in healthy 
travellers with risk of deep vein thrombosis (DVT) where 
beneficial effects of Pycnogenol have been reported when it
was either given alone or in combination (60,61). Furthermore, 
beneficial effects of Pycnogenol supplementation in patients
with venous ulcers have been demonstrated (62). Based on the 
pathophysiology of DVT and motion sickness and biological 
profiles of Pycnogenol, and ginger extract, a rational of
development of a combination product Zinopin was developed 
by Scurr and Gulati (63), which was followed up by a clinical 
study in travellers undertaking long-haul flight, beneficial
effects of Zinopin in DVT symptoms and incidence on motion 
sickness have been reported (64).
Hypertension
Supplementation with Pycnogenol over a period of 8 weeks 
significantly reduced systolic blood pressure; however
diastolic component was not changed (49). This observation 
supports its effect on stress induced component, by virtue of 
its vasodilatory effect through NO release by endothelial cells. 
In another placebo-controlled study in hypertensive patients 
receiving regular antihypertensive medication nifedipine, 
Pycnogenol supplementation caused decrease in nifedipine 
consumption to achieve same antihypertensive response. Blood 
samples analysis showed that Pycnogenol increased the levels 
of vasodilatory factors NO and prostacyclin and reduced the 
level of vasoconstrictor factor endothelin-1 (52).
Diabetes and diabetic retinopathy
There is experimental and clinical evidence to support that 
diabetes is associated with elevated blood levels of lipid 
peroxidation products (65-67) and role of oxidative stress 
is well documented (68,69). Since hyperglycemia, elevated 
blood lipid levels, increased oxidizability of LDL, decreased 
endogenous antioxidant enzyme system and enhanced platelet 
aggregation are associated with diabetes and related conditions 
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such as diabetic retinopathy and other cardiovascular 
complications, Pycnogenol by working through the above 
mentioned target parameters produce beneficial effects in
diabetes in animal models and in clinical studies (30-32, 
70,71)
Pycnogenol lowered fasting and postprandial blood 
glucose levels in a dose dependent manner and improved 
endothelial functions by lowering endothelin-1 level and 
increasing prostacyclin and NO concentration in blood (70). 
These results were confirmed in a placebo-controlled, double
blind study in diabetic patients (71). Pycnogenol has been 
shown to produce beneficial effects in diabetic retinopathy
(8-9). Capillary permeability index was significantly reduced
in both eyes after Pycnogenol treatment when measured 
using fluorescence angiography. In another multicenter
study carried out in Germany in 1169 patients with diabetic 
retinopathy, Pycnogenol administration for six months not 
only stopped deterioration of visual acuity but visual acuity 
index was improved in some cases (9). Furthermore, its ability 
in improving blood lipid profile in diabetic patients has an
important systemic role in the clinical management of this 
condition (8). 
 In conclusion, Pycnogenol maintains or improves 
cardiovascular health and glucose control by (i) optimizing 
the release of NO from endothelium, it produces blood vessel 
relaxation and antiplatelet effects resulting in better circulation, 
(ii) reducing blood pressure in mild to moderate hypertension, 
(iii) improving blood lipid profile, reducing peroxidation of
LDL and thus cardiovascular disease risks, (iv) reducing blood 
sugar levels and inhibiting oxidative stress and thus the risk of 
diabetes, and (v) “capillary sealing” effect which is suggested 
to be the basis for reduction of retinal microbleedings and 
exudation in diabetic retinopathy.
NUTRIGENOMICS
Pycnogenol has been shown to have fundamental role in 
the antioxidant network recycling the ascorbyl radical and 
protecting vitamin E against oxidation (23). It has a strong 
free radical scavenging activity against ROS and reactive 
nitrogen species (13). In the same study it was demonstrated 
that pre-treatment of monocyte-macrophage cell line (RAW 
264.7) with Pycnogenol for 24 hours before the administration 
of LPS and IFN-γ was associated to a dose-dependent decrease 
of nitrite and nitrate generation (13). Although this effect could 
be the result of a direct free radical scavenging activity against 
NO, the authors observed a reduction in the expression of the 
inducible form of NOS, giving a first indication that gene
expression modulatory effects play a key role in the protective 
mechanism exerted by Pycnogenol. Using a dual luciferase 
reporter gene assay that reveals the NF-κB-dependent gene 
expression induced by IFN-γ in RAW 264.7 cell line. One hour 
incubation with procyanidins was associated with different 
aspects towards gene expression, depending on the degree of 
polymerization: Pycnogenol and trimeric procyanidin enhanced 
the NF-κB-dependent gene expression, while monomers and 
dimers suppressed it (72). Bito et al (73) reported that 12 
hour pretreatment with Pycnogenol significantly inhibited
in a dose-dependent manner IFN-γ induced expression of 
ICAM-1 in the human immortalized keratinocytes cell line 
HaCAT. This observations pairs with the reported modulatory 
effects of Pycnogenol on the adhesion of Jurkat T cells to 
activated keratinocytes in a cocultutre assay (74). Using gel 
mobility shift assay, it was identified STAT-1 and IRF-1 as
two transcription factors affected by Pycnogenol, critical for 
IFN-γ dependent gene activation (74).
Cho et al (39) confirmed that Pycnogenol pretreatment 
prevented the activation of both NF-κB and AP-1 in activated 
RAW 264.7 cell line. They also found that such a pretreatment 
abolished LPS-induced IκB (an inhibitory protein that 
associates with NF-kB) degradation and downregulated IL-1β 
gene expression in RAW 264.7 and IL-2 gene expression in 
human T-cell line Jurkat E6.1. Pycnogenol ability to inhibit 
NF-κB activation and VCAM-1 and ICAM-1 expression was 
also reported in TNF-α-treated human umbilical endothelial 
cells (25). Pycnogenol treatment of human keratinocytes 
(HaCaT) inhibited in a concentration dependent manner UVR-
induced NF-kB dependent gene expression suggesting a role of 
Pycnogenol in protecting human skin against erythema (37).
Application of cDNA array techniques 
Complementary DNA (cDNA) arrays are global expression 
analyses tools that have been recently applied also to nutrition 
science providing information on how nutrients act at molecular 
level, regulating gene functions, and signal transduction 
pathways. Application of arrays to nutrigenomics will lead to 
discoveries in this field and may allow to treat or prevent life
style-related diseases. cDNA arrays consist of high density 
nylon, plastic glass or silica supports bearing immobilized 
sequences complementary to thousands genes. Supports are 
hybridized with labeled cDNA sequences obtained by reverse 
transcription of mRNA prepared from cells and tissues and 
resulting hybridization signal are compared to controls.
Rihn et al (74) reported that 24 hour supplementation 
of Pycnogenol is associated to significant modulation of 39
out of the 83 genes detected in a commercially available 
human cDNA array bearing a total of 588 genes in human 
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cells keratinocyte line HaCaT. Among modulated genes, it is 
worth mentioning that two genes coding calgranulins A and B, 
members of the highly conserved S100 family of low weight 
calcium-binding proteins, which are known to accumulated 
in psoriasis and various dermatitis conditions.
Targeting to better understanding of the anti-inflammatory
and putative anticancer properties of Pycnogenol, we 
recently applied a genomic analysis method to human tumor 
monocytic U397 cell line. U397 cells are model for monocyte 
to macrophage differentiation studies and are currently used in 
many laboratories in inflammatory and tumorogenicity studies.
Preliminary unpublished results suggest that Pycnogenol 
treatment is associated with a down regulation of gene 
encoding for monogenic hyperproliferative proteins and an 
upregulation of genes coding for proliferation check-point 
proteins. We also found a downregulation of hCDC10 and 
upregulation of KOX15 genes in Pycnogenol-treated U937 
cells (75,76). Gene expression profiling of cancer cell lines
challenged by procyanidins provide clues on the molecular 
pathways that are related to a putative anticancer property of 
Pycnogenol. It is important to stress that these observations, 
even though of interest, must be considered preliminary and 
confirmation is necessary before reaching any final conclusion
about the effective role of pine bark procyanidins on gene 
expression in human cancer cells. The application of array 
technology to nutrition will help the comprehension of nutrient 
effects, as well as molecular mechanisms underlying them, 
on human health and how nutrition influences the normal
homeostasis and physiology.
ACKNOWLEDGMENTS
The author thanks Dr F. Virgili at the National Institute 
for Food and Nutrition Research, Rome, Italy for valuable 
contribution in preparing this review. 
REFERENCES
1. Maritime Pine Bark Extract – USP 28. United States 
Pharamacopeial Convention, Inc. The United States 
Pharmcopeia official from January 1, 2004; 2024-2025.
2. Rohdewald PJ. Pycnogenol®, French maritime pine bark 
extract. Encyclopedia of Dietary Supplements 2005; 545-
552.
3. Drehsen G. From ancient pine bark uses to Pycnogenol. 
In: L. Packer, M. Hiramatsu, T. Yoshikawa, editors. 
Antioxidant Food Supplements in Human Health. 
Academic Press, 1999; 20: 311-322.
4. Gulati OP. Pycnogenol® in venous disorders: A review. 
Eur Bull Drug Res 1999; 7: 8-13.
5. Arcangeli P. Pycnogenol® in chronic venous insufficiency.
Fitoterapia 2000; 71: 236-244.
6. Petrassi C, Mastromarino A, Spartera C. Pycnogenol® 
in chronic venous insufficiency. Phytomedicine 2000; 7: 
383-388.
7. Koch R. Comparative study of Venostasin® and Pycno-
genol® in chronic venous insufficiency. Phytother Res 
2002; 16: S1-S5.
8. Spadea L, Balestrazzi E. Treatment of vascular retinopathies 
with Pycnogenol. Pythother Res 2001; 15: 1-5.
9. Schönlau F, Rohdewald P. Pycnogenol® for diabetic 
retinopathy: A review. Int Ophthalmol 2002; 24: 161-
171.
10. Rohdewald, P. A review of the French maritime pine bark 
extract (Pycnogenol®), a herbal medication with a diverse 
clinical pharmacology. Int J Clin Pharmacol Ther 2002; 
40: 158-168.
11. Watson RR. Review: Pycnogenol® and cardiovascular 
health. Evidence Based Integr Med 2003; 1: 27-32.
12. Blumenthal, M. Pycnogenol (French Maritime Pine 
Bark Extract) Pinus Pinaster Aiton subsp. atlantica. The 
American Botanical Council Guide to Herbs 2003 ; 369-
373.
13. Virgili F, Kim D, Packer L. Procyanidins extracted from 
pine bark protect α-tocopherol in ECV 304 endothelial 
cells challenged by activated RAW 264.7 macrophages: 
role of nitric oxide and peroxynitrite. FEBS Letters 1998; 
431: 315-318.
14. Virgili F, Kobuchi H, Noda Y, Cossins E, Packer L. 
Procyanidins from Pinus maritima bark: Antioxidant 
activity, effects on the immune system and modulation 
of nitrogen monoxide metabolism. In: L. Packer, M. 
Hiramatsu, T. Yoshikawa, editors. Antioxidant Food 
Supplements in Human Health. Academic Press 1999; 
21: 323-342.
15. Packer L, Rimbach G, Virgili F. Antioxidant activity and 
biologic properties of a procyanidin-rich extract from the 
pine (Pinus maritima) bark, Pycnogenol. Free Rad Biol 
Med 1999; 27: 704-724.
16. Rohdewald P. Pycnogenol®. In: Catherine A, Rice E, 
Packer L, editors. Flavonoids in Health and Disease. 
Marcel Dekker Inc., NY. 1998; 17: 405-419.
17. Blazso G, Gabor M, Sibbel R, Rohdewald P. An anti-
inflammatory and superoxide radical scavenging activities
of a procyanidins containing extract from the bark of Pinus 
pinaster sol. and its fractions. Pharm Parmacol Lett 1994; 
3: 217-220.
18. Rong Y, Li L, Shah V, Lau BHS. Pycnogenol protects 
55
Biomed Rev 16, 2005
The nutraceutical Pycnogenol
vascular endothelial cells from t-butyl hydroperoxide 
induced oxidant injury. Biotechnol Ther 1995; 5: 117-
126.
19. Noda Y, Anzai K, Mori A, Kohno M, Shinmei M, Packer 
L. Hydroxyl and superoxide anion radical scavenging 
activities of natural source antioxidants using the 
computerized, JES-FR30 ESR spectrometer system. 
Biochem Mol Biol Int 1997; 42: 35-44.
20. Nelson AB, Lau BHS, Ide N, Rong Y. Pycnogenol inhibits 
macrophage oxidative burst, lipoprotein oxidation and 
hydroxyl radical-induced DNA damage. Drug Dev Indust 
Pharm 1998; 24: 139-144.
21. Chida M, Suzuki K, Nakanishi-Ueda T, Ueda T, Yasuhara 
H, Koide R, Armstrong D. In vitro testing of antioxidants 
and biochemical end-points in bovine retinal tissue. 
Ophthalmol Res 1999; 31: 407-415.
22. Feng WH, Wei HL, Liu GT. Effect of Pycnogenol® on 
the toxicity of heart, bone marrow and immune organs 
as induced by antitumor drugs. Phytomedicine 2002; 9: 
414-418.
23. Cossins E, Lee R, Packer L. ESR studies of vitamin 
C regeneration, order of reactivity of natural source 
phytochemical preparations.Biochem Mol Biol Int 1998; 
45: 583-597.
24. Kim J, Chehade J, Pinnas JL, Mooradian AD. Effect of 
selected antioxidants on malondialdehyde modification
of proteins. Nutrition 2000; 16: 1079-1081.
25. Peng QL, Buz’Zard AR, Lau BHS. Research report: 
Pycnogenol® protects neurones from amyloid β peptide-
induced apoptosis. Mol Brain Res 2002; 104: 55-65.
26. Sharma SC, Sharma S, Gulati O. Pycnogenol® prevents 
haemolytic injury in G6PD deficient human erythrocytes.
Phytother Res 2003; 17: 671-674.
27. Bayeta E, Bejamin MS, Lau HS. Pycnogenol inhibits 
generation of inflammatory mediators in macrophages.
Nutr Res 2000; 20: 249-259.
28. Wei ZH, Peng QL, Lau BHS. Pycnogenol® enhances 
endothelial cell antioxidant defenses. Redox Rep 1997; 
3: 219-224.
29. Janisch K, Hippeli S, Dornisch K, Kern S, Elstner EF. 
Determination of the antioxidative potential of human 
plasma after supplementation with Pycnogenol® and whey. 
Food Res Int 2002; 35: 257-266.
30. Maritim A, Dene BA, Sanders RA, Watkins JB. Effect of 
Pycnogenol® treatment on oxidative stress in streptozoitin-
induced diabetic rats. J Biochem Mol Toxicol 2003; 17: 
193-199.
31. Berryman AM, Maritim AC, Sanders RA, Watkins JB. 
Influence of treatment of diabetic rats with combinations
of Pycnogenol, β carotene, and α-lipoic acid on parameters 
of oxidative stress. J Biochem Mol Toxicol 2004; 18: 345-
352. 
32. Dene BA, Maritim AC, Sanders RA, Watkins JB. Effects 
of antioxidant treatment on normal and diabetic rat retinal 
enzyme activities. J Ocular Pharmacol Ther 2005; 21: 
28-35. 
33. Devaraj S, Kaul N, Schönlau F, Rohdewald P, Jialal 
I. Supplementation with a pine bark extract rich in 
polyphenols increases plasma antioxidant capacity and 
alters plasma lipoprotein profile. Lipids 2002; 37: 931-
934.
34. Durackova Z, Trebaticky B, Novotny V, Zitnanova I, Breza 
J. Lipid metabolism and erectile function improvement by 
Pycnogenol®, extract from the bark of Pinus pinaster in 
patients suffering from erectile dysfunction, a pilot study. 
Nutr Res 2003; 23: 1189-1198.
35. Blazso G, Rohdewald P, Sibbel R, Gabor M. Anti-
inflammatory activities of procyanidin-containing extracts
from Pinus pinaster sol. Proceedings of the International 
Bioflavonoid Symposium, Vienna, Austria, Antus S,
Gabor M, Vetschera K, editors. July 16-19, 1995; 231-
238.
36. Blazso G, Gabor M, Rohdewald P. Anti-inflammatory
activities of procyanidin containing extracts from Pinus 
pinaster Ait. after oral and cutaneous application. 
Pharmazie 1997; 52: 380-382.
37. Saliou C, Rimbach G, Moini H, McLaughlin L, Hosseini 
S, Lee J, et al. Solar ultraviolet-induced erythema in 
human skin and nuclear factor-kappa-B-dependent gene 
expression in keratinocytes are modified by French
maritime pine bark extract. Free Radical Biol Med 2001; 
30: 154-160.
38. Sime S, Reeve V E. Protection from inflammation,
immunosuppression and carcinogenesis induced by UV 
radiation in mice by topical Pycnogenol®. Photochem 
Photobiol 2004; 79: 193-198.
39. Cho K-J, Yun C-H, Yoon D-Y, Cho Y-S, Rimbach G, 
Packer L, et al. Effect of bioflavonoids extracted from
the bark of Pinus maritime on proinflammatory cytokine
interleukin-1 production in lipopolysaccharide-stimulated 
raw 264.7. Toxicol Appl Pharmacol 2000; 1687: 64-71.
40. Grimm T, Schäfer A, Högger P. Antioxidant activity and 
inhibition of matrix metalloproteinases by metabolites of 
maritime pine bark extract (Pycnogenol). Free Radical 
Biol Med 2004; 36: 811-822.
41. Sharma SC, Sharma S, Gulati OP. Pycnogenol® inhibits 
56
Biomed Rev 16, 2005
Gulati
the release of histamine from mast cells. Phytother Res 
2003; 17: 66-69.
42. Blazso G, Gabor M, Schönlau F, Rohdewald P. Pycno-
genol® accelerates wound healing and reduces scar 
formation. Phytother Res 2005; 18: 579-581.
43. Ni Z, Mu Y, Gulati O. Treatment of melasma with 
Pycnogenol®. Pytother Res 2002; 16: 567-571.
44. Roseff SJ. Improvement in sperm quality and function 
with French maritime pine tree bark extract. J Reprod 
Med 2002; 47: 821-824.
45. Kimbrough C, Chun M, Dela Roca G, Lau BHS. 
Pycnogenol® chewing gum minimizes gingival bleeding 
and plaque formation. Phytomedicine 2002; 9: 410-413.
46. Stanislavov R, Nikolova V. Treatment of erectile 
dysfunction with Pycnogenol® and L-arginine. J Sex 
Marital Ther 2003; 29:207-213.
47. Pütter M, Grotemeyer KHM, Würthwein G, Araghi-
Niknam M, Watson RR, Hosseini S, et al. Inhibition of 
smoking-induced platelet aggregation by aspirin and 
Pycnogenol. Thromb Res 1999; 95: 155-161.
48. Araghi-Niknam M, Hosseini S, Larson D, Rohdewald P, 
Watson RR. Pine bark extract reduces platelet aggregation. 
Integr Med 1999; 2: 73-77.
49. Hosseini S, Lee J, Sepulveda R T, Rohdewald P, Watson 
RR. A randomized, double-blind, placebo-controlled, 
prospective, 16 week crossover study to determine the 
role of Pycnogenol in modifying blood pressure in mildly 
hypertensive patients. Nutr Res 2001; 21: 1251-1260.
50. Wang S, Tan D, Zhao Y, Gao G, Gao X, Hu L. The effect 
of Pycnogenol® on the microcirculation, platelet function 
and ischemic myocardium in patients with coronary artery 
diseases. Eur Bull Drug Res 1999; 7: 19-25.
51. Kohama T, Suzuki N, Ohno S, Inoue M. Analgesic efficacy
of French maritime pine bark extract in dysmenorrhea 
– An open clinical trial. J Reprod Med 2004; 49: 828-
832.
52. Liu X, Wei J, Tan F, Zhou S, Würthwein G, Rohdewald P. 
Pycnogenol® French maritime pine bark extract improves 
endothelial function of hypertensive patients. Life Sci 
2004; 74: 855-862.
53 Segger D, Schönlau F. Supplementation with Evelle® 
improves skin smoothness and elasticity in a double blind, 
placebo-controlled study with 62 women. J Dermatol 
Treat 2004; 15: 222-226.
54 Hosseini S, Pishnamazi S, Sadrzadeh MH, Farid F, Farid 
R. Watson RR. Pycnogenol® in the management of asthma. 
J Med Food 2000; 4: 201-209.
55 Lau BHS, Riesen SK, Truong KP, Lau EW, Rohdewald P, 
Barreta RA. Pycnogenol® as an adjunct in the management 
of childhood asthma. J Asthma 2004; 41: 825-832.
56. Fitzpatrick DF, Bing B, Rohdewald P. Endothelium-
dependent vascular effects of Pycnogenol. J Cardiovasc 
Pharmacol 1998; 32: 509-515.
57. Belkhiri A, Richards C, Whaley M, McQueen SA, 
Orr FW. Increased expression of activated matrix 
metalloproteinase-2 by human endothelial cells after 
sublethal H2O2 exposure. Lab Invest 2004; 77: 533-539.
58. Grimm T, Schäfer A, Högger P. Antioxidant activity and 
inhibition of matrix metalloproteinases by metabolites of 
maritime pine bark extract (Pycnogenol). Free Rad Biol 
Med 2004; 36: 811-822.
59. Schönlau F. The cosmeceutical Pycnogenol®. J Appl 
Cosmetol 2002; 20: 241-247.
60. Cesarone MR, Belcaro G, Nicolaides AN, Ricci A, 
Geroulakos G, et al. Prevention of venous thrombosis 
in long-haul flights with Flite tabs: The Lonflit-Flite
randomized, controlled trial. Angiology 2003; 54: 531-
539.
61. Belcaro G, Cesarone MR, Rohdewald P, Ricci A, Ippolito 
E, Dugall M, et al. Prevention of venous thrombosis and 
thrombophlebitis in long haul flights with Pycnogenol®. 
Clin Appl Thromb Hemost 2004; 10: 373-377.
62. Belcaro G, Cesarone MR, Errichi BM, Ledda A, Di 
Renzo A, Stuard S, et al. Venous ulcers: Microcirculatory 
improvement and faster healing with local use of 
Pycnogenol®. Angiology 2005; 56: 699-705.
63. Scurr JH, Gulati OP. Zinopin® - the rationale of its use as 
a food supplement in traveller’s thrombosis and motion 
sickness Phytother Res 2004; 18: 687-695.
64. Scurr JH, Gulati OP. Zinopin® - its use as a food 
supplement in traveller’s thrombosis, oedema and motion 
sickness. Eur Bull Drug Res 2005; 13, 77-81.
65. Garg MC, Singh KP, Bansal DD. Effect of viatamin E 
supplementation on antioxidant status of diabetic rats. 
Med Sci Res 1996; 24:325-326.
66. Valazquez E, Winocour PH, Kesteven P, Alberti KGM, 
Laker MF. Relation of lipid peroxides to macrovascular 
disease in type 2 diabetes. Diabet Med 1991; 8: 752-
758.
67. Nourooz-Zadeh J, Rahimi A, Tajaddini-Sarmadi J, 
Tritschler H, Rosen P, Halliwell B, et al. Relationships 
between plasma measures of oxidative stress and 
metabolic control in NIDDM. Diabetologia 1997; 40: 
647-653.
68. Douillet C, Chanceerelle Y, Cruz C, Marocles , Kergonou 
57
Biomed Rev 16, 2005
The nutraceutical Pycnogenol
JF, Renaud S, et al. High dosage vitamin E. Effect 
of oxidative stress and serum lipids distribution in 
Streptoztocin-induced diabetic rats. Biochem Med Metab 
Biol 1993; 50: 265-276.
69. Kahler W, Kuklinsiki B, Ruhlmann C, Pléotz C. Diabetes 
mellitus - a free radical-associated disease: effects of 
adjuant supplementation of antioxidants. In: Gris FA, 
Wessel K, editors. The Role of Antioxidants in Diabetes 
Mellitus: Oxygen Radicals and Antioxidants in Diabetes. 
Verlag Grouppe 1993; 33-53. 
70. Liu X, Ha-Jun Z, Rohdewald P. French maritime pine bark 
extract Pycnogenol® lowers glucose dose dependently in 
patients with diabetes type II. Diabetes Care 2003; 27: 
839.
71. Liu X, Wei J, Tan F, Zhou S, Wèrthwein G, Rohdewald 
P. Antidiabetic effects of Pycnogenol®, French maritime 
pine bark extract, in patients with diabetes type II. Life 
Sci 2004; 75: 2505-2513.
72. Park YC, Rimbach G, Saliou C, Valacchi G, Packer L. 
Activity of monomeric, dimeric, and trimeric flavonoids
on NO production, TNF-α secretion, and NF-κB-
dependent gene expression in RAW 264.7 macrophages. 
FEBS Lett 2000, 465: 93-97
73. Bito T, Roy S, Sen CK, Packer L. Pine bark extract 
Pycnogenol downregulates IFN-γ-induced adhesion of 
T cells to human keratinocytes by inhibiting inducible 
ICAM-1 expression. Free Radical Biol Med 2000, 28: 
219-227.
74. Rihn B, Saliou C, Bottin MC, Keith G, Packer L. From 
ancient remedies to modern therapeutics, Pine bark uses in 
skin disorders revisited. Phytother Res 2001; 15: 76-78.
75. Virgili F, Ambra R, Canali R, Gulati O. Pycnogenol in 
cancer chemoprevention. In: Bagchi D, Preuss G, editors. 
Phytopharmaceuticals in Cancer Chemoprevention. 2005; 
29; 491-508.
76. Canali R, Ambra R, Gulati O, Virgili F. Antioxidant and 
gene regulatory properties of procyanidins. Rimbach/
Packer: Nutrigenomics - The Role of Oxidants and 
Antioxidants in Differential Gene Expression. 2005; 18: 
379-395.
